What is the difference between GHRP-6 and Hexarelin?

GHRP-6 is classified as: Synthetic growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist; first-described growth hormone-releasing hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys). Hexarelin is classified as: Synthetic growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist; growth hormone-releasing peptide (GHRP) hexapeptide. GHRP-6 is investigational and is not an approved medicine. Hexarelin is investigational and is not an approved medicine.

Is GHRP-6 or Hexarelin approved?

GHRP-6 is investigational and is not an approved medicine. Hexarelin is investigational and is not an approved medicine. Regulatory status by region is set out in the table above.

How much clinical trial evidence is tracked for GHRP-6 and Hexarelin?

Peptide Science Daily tracks 40 registered clinical trials for GHRP-6 (evidence grade C) and 0 for Hexarelin (evidence grade C).

Compound comparison

GHRP-6 vs Hexarelin

This page sets GHRP-6 and Hexarelin side by side using the data recorded on Peptide Science Daily: drug class, mechanism of action, regulatory status by region, the evidence grade assigned here, and the number of clinical trials tracked. It is a neutral, factual comparison and does not rank either compound or recommend one over the other.

Side-by-side comparison

Class: GHRP-6
Synthetic growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist; first-described growth hormone-releasing hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys)
Hexarelin
Synthetic growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist; growth hormone-releasing peptide (GHRP) hexapeptide
Mechanism: GHRP-6
In plain terms, GHRP-6 acts like the hunger hormone ghrelin, prompting the pituitary to release growth hormone and increasing appetite.
Hexarelin
In plain terms, hexarelin tells the pituitary gland to release a pulse of the body's own growth hormone, and in laboratory studies it can also act directly on the heart and blood vessels.
United States (FDA): GHRP-6
Not approved for any indication; an unapproved growth hormone secretagogue with no marketed product.
Hexarelin
Not approved for any indication; an unapproved growth hormone secretagogue with no marketed product.
European Union (EMA): GHRP-6
No EMA marketing authorisation; not an approved medicine in the EU.
Hexarelin
No EMA marketing authorisation; not an approved medicine in the EU.
Australia (TGA): GHRP-6
Not on the Australian Register of Therapeutic Goods (ARTG); an unapproved substance with no registered product.
Hexarelin
Not on the Australian Register of Therapeutic Goods (ARTG); an unapproved substance with no registered product.
WADA: GHRP-6
Prohibited at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics); growth hormone secretagogues including GHRP-6 are explicitly covered.
Hexarelin
Prohibited at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics); growth hormone secretagogues and growth hormone-releasing peptides (GHRPs) are explicitly covered.
Evidence grade: GHRP-6
C
Hexarelin
C
Tracked clinical trials: GHRP-6
40
Hexarelin
0
Full profile: GHRP-6
GHRP-6 profile
Hexarelin
Hexarelin profile

Comparison of GHRP-6 and Hexarelin by class, mechanism, regulatory status by region, evidence grade, and number of tracked clinical trials.
Attribute	GHRP-6	Hexarelin
Class	Synthetic growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist; first-described growth hormone-releasing hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys)	Synthetic growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist; growth hormone-releasing peptide (GHRP) hexapeptide
Mechanism	In plain terms, GHRP-6 acts like the hunger hormone ghrelin, prompting the pituitary to release growth hormone and increasing appetite.	In plain terms, hexarelin tells the pituitary gland to release a pulse of the body's own growth hormone, and in laboratory studies it can also act directly on the heart and blood vessels.
United States (FDA)	Not approved for any indication; an unapproved growth hormone secretagogue with no marketed product.	Not approved for any indication; an unapproved growth hormone secretagogue with no marketed product.
European Union (EMA)	No EMA marketing authorisation; not an approved medicine in the EU.	No EMA marketing authorisation; not an approved medicine in the EU.
Australia (TGA)	Not on the Australian Register of Therapeutic Goods (ARTG); an unapproved substance with no registered product.	Not on the Australian Register of Therapeutic Goods (ARTG); an unapproved substance with no registered product.
WADA	Prohibited at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics); growth hormone secretagogues including GHRP-6 are explicitly covered.	Prohibited at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics); growth hormone secretagogues and growth hormone-releasing peptides (GHRPs) are explicitly covered.
Evidence grade	C	C
Tracked clinical trials	40	0
Full profile	GHRP-6 profile	Hexarelin profile

Common questions

What is the difference between GHRP-6 and Hexarelin?: GHRP-6 is classified as: Synthetic growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist; first-described growth hormone-releasing hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys). Hexarelin is classified as: Synthetic growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist; growth hormone-releasing peptide (GHRP) hexapeptide. GHRP-6 is investigational and is not an approved medicine. Hexarelin is investigational and is not an approved medicine.
Is GHRP-6 or Hexarelin approved?: GHRP-6 is investigational and is not an approved medicine. Hexarelin is investigational and is not an approved medicine. Regulatory status by region is set out in the table above.
How much clinical trial evidence is tracked for GHRP-6 and Hexarelin?: Peptide Science Daily tracks 40 registered clinical trials for GHRP-6 (evidence grade C) and 0 for Hexarelin (evidence grade C).